fen-o-FI-brate 
Therapeutic Classification: lipid-lowering agents
Pharmacologic Classification: fibric acid derivatives
Absorption: Well absorbed (60%) after oral administration; absorption ↑ by food.
Distribution: Unknown.
Protein Binding: 99%.
Metabolism/Excretion: Rapidly converted to fenofibric acid, which is the active metabolite; fenofibric acid is metabolized by the liver. Fenofibric acid and its metabolites are primarily excreted in urine (60%).
Half-life: 20 hr.
Contraindicated in:
Use Cautiously in:
CV: arrhythmia, DEEP VEIN THROMBOSIS.
Derm: rash, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, urticaria.
GI: ↑ liver enzymes, cholelithiasis, HEPATOTOXICITY, pancreatitis.
Metab: ↓ HDL levels.
MS: rhabdomyolysis.
Neuro: fatigue/weakness, headache.
Resp: INTERSTITIAL LUNG DISEASE, PULMONARY EMBOLISM.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Primary Hypercholesterolemia/Mixed Dyslipidemia
Renal Impairment
Hypertriglyceridemia
Renal Impairment
(Generic available)
Antara, Fenoglide, Lipofen, Tricor, Triglide
NDC Code*
